



- (51) **International Patent Classification:**
C07D 409/14 (2006.01) *A61K 31/506* (2006.01)
- (21) **International Application Number:**
PCT/US2014/067385
- (22) **International Filing Date:**
25 November 2014 (25.11.2014)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/911,341 3 December 2013 (03.12.2013) US
- (71) **Applicant:** AMGEN INC. [US/US]; One Amgen Center Dr., Thousand Oaks, California 91320-1799 (US).
- (72) **Inventors:** STANTON, Mary; 169 Monsignor O'Brien Highway, Unit 211, Cambridge, Massachusetts 02141 (US). BIO, Matthew; 433 E. Micheltorena Street, Santa Barbara, California 93101 (US). PETERSON, Matthew; 14 Fruit Street, Hopkinton, Massachusetts 01748 (US).
- (74) **Agent:** REDDY, G. Prabhakar; One Amgen Center Dr., Thousand Oaks, California 91320-1799 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Published:

— with international search report (Art. 21(3))

(54) **Title:** CRYSTALLINE FORMS OF N-4-((3-(2-AMINO-4-PYRIMIDINYL) - 2-PYRIDINYL)OXY)PHENYL)-4-(4-METHYL-2-THIENYL)-1-PHTHALAZINAMINE PHARMACEUTICALLY ACCEPTABLE SALTS AND USES THEREOF

5

FIGURE 4



(57) **Abstract:** The present invention relates to crystalline forms and co-crystal forms of pharmaceutically acceptable salts of the compound, N-4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine (AMG 900, and pharmaceutical compositions comprising said crystalline and co-crystal forms thereof. The invention further provides uses of the crystalline forms and compositions, to treat cancer, including various types of solid tumors and hematologic cancer including myeloma and leukemia.